Physician profile
Michael F Cunningham
NPI 1366515405
$5,199.69
in general payments reported to CMS, 2019-2025
40 companies · $1,327 in 2025
The $1,327 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,234 · 2020: $351 · 2021: $504 · 2022: $867 · 2023: $380 · 2024: $536 · 2025: $1,327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,242.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neotract INC. | $924.90 | 2019-2020 | |
| Astellas Pharma US INC | $501.55 | 2019-2025 | Myrbetriq, Xtandi |
| Pfizer INC. | $465.70 | 2019-2025 | |
| Teleflex LLC | $429.20 | 2020-2025 | Urolift, Barrigel |
| Abbvie INC. | $277.80 | 2021-2025 | |
| Endo USA, INC. | $258.18 | 2024-2025 | Xiaflex, Aveed |
| Endo Pharmaceuticals INC. | $220.47 | 2019-2024 | Aveed, Xiaflex, Edex |
| Olympus America INC. | $194.58 | 2022-2025 | Itind System |
| Urogen Pharma, INC. | $184.77 | 2021-2025 | Jelmyto |
| Antares Pharma, INC. | $168.90 | 2019-2025 | Xyosted |
| Boston Scientific Corporation | $149.26 | 2019-2025 | Rezum Generator |
| Cvrx, INC. | $144.32 | 2021 | |
| Sumitomo Pharma America, INC. | $124.03 | 2023-2025 | Gemtesa, Orgovyx |
| Profound Medical Corp. | $120.81 | 2022 | |
| Immunitybio, INC. | $117.80 | 2025 |
Show all 39 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$739.66 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.